Nycomed announces costs cuts after bad third-quarter:
This article was originally published in Clinica
Nycomed, the Norwegian manufacturer of contrast agents and pharmaceuticals, intends to cut annual costs by around 10% or NKr 600 million ($ 93 million) by 1998. It expects to cut 700 jobs, 13% of its workforce. The company announced the plan with the latest quarterly results. In the first nine months Nycomed's net income fell 32% to NKr 898 million and group sales were down 7% to NKr 5,794 million. Contrast agent revenues were the reason for the deterioration as they declined 9% to NKr 3,496 million while operating profits were down 22% to NKr 1,395 million.
You may also be interested in...
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.
In second letter this year targeting email communications, OPDP says that putting the methotrexate oral solution’s risk information below the signature block does not offer ‘prominence and readability’ comparable to the information on the drug’s effectiveness for the treatment of acute lymphoblastic leukemia that was in the body of the email.